Capital Advisors Ltd’s Lineage Cell Therapeutics LCTX Stock Holding History

Capital Advisors Ltd’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-38	Closed	–	–	1378
2022 Q2	$0	Buy	+38	New	+$50	﹤0.01%	1172

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Capital Advisors Ltd's LCTX Position: Q3 2022 in Review

Capital Advisors Ltd sold out of Lineage Cell Therapeutics (LCTX) in Q3 2022, closing a stake of 38 shares.

Capital Advisors Ltd first reported a position in LCTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 105 funds tracked by Wall St. Rank hold LCTX as of Q3 2022.

Capital Advisors Ltd reported no remaining Lineage Cell Therapeutics position as of Q3 2022 after selling out during the quarter.
Capital Advisors Ltd sold 38 Lineage Cell Therapeutics shares in Q3 2022.
Capital Advisors Ltd first reported a position in Lineage Cell Therapeutics in Q2 2022 and held it in 1 quarter.
Capital Advisors Ltd's Lineage Cell Therapeutics position peaked at $0 in Q2 2022.
105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.